Creating new perspectives in healthcare

We are driven by the purpose of improving lives through pharmaceutical innovation. Knowing that our knowledge and expertise can concretely improve people’s health and well-being, we strive every day to improve healthcare by researching and developing innovative solutions for disease prevention, management, and cure. Our daily work is inspired by the firm belief that everyone deserves access to healthcare that empowers them to live their lives to the fullest.

Mission

Italfarmaco Group is a leading organization that specializes in the development, manufacture, and marketing of prescription and non-prescription products. Our primary objective is to increase our investment in research and development activities, with a particular focus on developing high-quality, effective solutions for patients and healthcare providers worldwide. We are also committed to developing innovative treatments for specialty and rare diseases. Our organization is dedicated to excellence and we work to achieve sustainable growth and have a positive impact on society and the environment.

Mission and Vision of Italfarmaco SpA

Vision

Embedded in our family-owned heritage, our company is dedicated to sustainable success, striving to be a global leader in pharmaceutical innovation and excellence. We focus on expanding our product portfolio, which includes branded prescription and non-prescription products with a particular focus on rare diseases. We are committed to consolidating our presence in global markets through a strategy that balances organic growth with strategic partnerships worldwide.

Our Values

Meet our Leaders

Francesco De Santis, Chairman Italfarmaco SpA

Francesco
De Santis

Chairman

Carlos Barallobre, CEO Italfarmaco SpA

Carlos
Barallobre

CEO

Where we are

90+ countries, 1 Global Vision

Map shows our worldwide presence with local branches and partners companies distributing our products in over 90 countries.

Link image to the Local Contacts page
  • Affiliate

  • Distribution / Licence agreements

  • Affiliate

  • Distribution / Licence agreements

A glance to our value

0 bn€

FCST GROSS
SALES 2024

0 %

PROPRIETARY
PRODUCTS

0 M

INVESTMENT IN MANUFACTURING
(2020-2024)

0 M

PRODUCT INDUSTRIAL
UNITS PER YEAR

Our production plants

We oversee the entire process of creating drugs, from start to finish, to ensure their quality as medicines. We have six advanced production facilities; in each, we manufacture different products: injectable and solid oral products in Milan; liquid oral products in Madrid and Santiago de Chile; semi-solid products in Barcelona; API products in Frosinone (Italy) and Salvador de Bahia manufacture. We also have Chemi Spa, an Italian pharmaceutical chemical company that produces complex molecules, including the synthesis of the active ingredient (API) and the pharmaceutical form of injectable drugs.

We continuously invest in technology to maintain modern, flexible facilities, a high production capacity, quality, safety, and environmental sustainability, as modern disease solutions require a contemporary approach.

Italfarmaco SpA has six production plants: two in Italy, two in Spain, one in Brazil and one in Chile
Our production plants - Italfarmaco SpA
Our production plants - Italfarmaco SpA
Our production plants - Italfarmaco SpA
Our production plants - Italfarmaco SpA
Our production plants - Italfarmaco SpA
Our production plants - Italfarmaco SpA
Our production plants - Italfarmaco SpA

Our History

Founded in 1938 in Milan, Italfarmaco has left a compelling mark on the national and international pharmaceutical landscape. From its establishment until the 1970s, the company steadily solidified its position, emerging as a key player in the industry. With a robust franchise in thrombosis and cardiovascular areas, Italfarmaco gained recognition as a force to be reckoned with in the Italian mid-market segment. But its story didn’t end there.

In 1976, Dr. Gastone De Santis joined the company, acquiring a stake and setting the stage for transformative leadership combining his passion for research and managerial activity. By 1980, he had assumed full control, becoming the chairman of the board of directors. That same year, his son, Francesco De Santis, stepped into the spotlight at just twenty-five years old. As managing director, and then as appointed Chairman, Francesco De Santis spearheaded an ambitious internationalization process that continues to this day.

Italfarmaco’s global expansion took various forms—licensing contracts, collaboration agreements, direct presence establishment and strategic acquisitions.

In 1991, the founding of Italfarmaco S.A. in Spain marked a pivotal moment, kicking-off the company’s expansion across Europe, the Americas, and Asia. Throughout this journey, Italfarmaco’s resolute focus on research and development has been the cornerstone of its success, with the consolidation of its footprints in several therapeutic areas such as women’s health and the focus on addressing significant unmet medical needs in rare diseases.

Today, Italfarmaco stands as a patient and innovation oriented, bridging borders and working in advancing healthcare and quality of life.